Skip to main content
Hauptrubriken
CME Facharzt-Training Webinare Zeitschriften Bücher e.Medpedia Podcast
Service
Jobbörse Info & Hilfe
Fachgebiete
Anästhesiologie Allgemeinmedizin Arbeitsmedizin Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kardiologie Neurologie Onkologie und Hämatologie Orthopädie und Unfallchirurgie Pädiatrie Pathologie Psychiatrie Radiologie Rechtsmedizin Urologie Zahnmedizin
Themen
Klimawandel und Gesundheit Neues aus dem Markt COVID-19 Praxis und Beruf Seltene Erkrankungen GOÄ & EBM Panorama
Sammlungen
Kasuistiken Algorithmen & Infografiken Blickdiagnosen Arthropedia FlapFinder (für Dermatochirurgen) Videos Kongressberichterstattung Medizin für Apothekerinnen und Apotheker Für Ärztinnen und Ärzte in Weiterbildung Für Medizinstudierende
Erweiterte Suche
Anmelden
nach oben
Current Neurology and Neuroscience Reports
Erschienen in: Current Neurology and Neuroscience Reports 7/2018

01.07.2018 | Demyelinating Disorders (J Bernard and M Cameron, Section Editors)

Caring for Women with Multiple Sclerosis Across the Lifespan

verfasst von: Kelsey Rankin, Riley Bove

Erschienen in: Current Neurology and Neuroscience Reports | Ausgabe 7/2018

Einloggen, um Zugang zu erhalten

Abstract

Purpose of Review

Caring for women with multiple sclerosis (MS), whose first symptoms typically begin during the childbearing years, requires a comprehensive approach to management across a range of reproductive exposures, and beyond through menopause.

Recent Findings

This article summarizes what is known about the disease course in women with MS, how it differs from men, and the current state of knowledge regarding effects of reproductive exposures (menarche, childbearing, menopause) on MS-related inflammation and neurodegeneration. Recent findings regarding pregnancy-associated relapses in the treatment era, protective effects of breastfeeding, and care for women during the menopausal transition are reviewed. Then, updated recommendations to guiding women during childbearing—including pre-conception counseling, discontinuation of MS therapies, and management of postpartum relapses—are provided. Whenever possible, areas of uncertainty and avenues for future research are highlighted.

Summary

From childhood through the postreproductive life stages, gender and hormonal exposures appear to shape an individual’s risk for MS, as well as the experience of living with MS.
Literatur
1.
2.
Maghzi AH, Ghazavi H, Ahsan M, et al. Increasing female preponderance of multiple sclerosis in Isfahan, Iran: a population-based study. Mult Scler. 2010;16:359–61.PubMedCrossRef
3.
Bove R, Chitnis T. The role of gender and sex hormones in determining the onset and outcome of multiple sclerosis. Mult Scler. 2014;20:520–6.PubMedCrossRef
4.
Houtchens M, Bove R. A case for gender-based approach to multiple sclerosis therapeutics. Front Neuroendocrinol 2018, in press.
5.
Ploughman M, Collins K, Wallack EM, et al. Women’s and men’s differing experiences of health, lifestyle, and aging with multiple sclerosis. Int J MS Care. 2017;19:165–71.PubMedPubMedCentralCrossRef
6.
Novo AM, Batista S, Tenente J, et al. Apathy in multiple sclerosis: gender matters. J Clin Neurosci. 2016;33:100–4.PubMedCrossRef
7.
• Theaudin M, Romero K, Feinstein A. In multiple sclerosis anxiety, not depression, is related to gender. Mult Scler. 2016;22:239–44. This study describes gender differences in anxiety coping and quality of life. It illuminates important differences in gender-based perception of health. PubMedCrossRef
8.
Miller A, Dishon S. Health-related quality of life in multiple sclerosis: the impact of disability, gender and employment status. Qual Life Res. 2006;15:259–71.PubMedCrossRef
9.
Cuello JP. Time to pregnancy in multiple sclerosis: a case-control study. Austin Journal of Clinical Neurology 2017.
10.
Marrie RA, Patten SB, Tremlett H, et al. Sex differences in comorbidity at diagnosis of multiple sclerosis: a population-based study. Neurology 2016.
11.
Marrie RA, Horwitz RI, Cutter G, Tyry T, Vollmer T. Association between comorbidity and clinical characteristics of MS. Acta Neurol Scand. 2011;124:135–41.PubMedCrossRef
12.
Marrie RA, Horwitz R, Cutter G, Tyry T. Cumulative impact of comorbidity on quality of life in MS. Acta Neurol Scand. 2012;125:180–6.PubMedCrossRef
13.
Dobos K, Healy B, Houtchens M. Preventive health-care access in severely disabled women with multiple sclerosis. International Journal of MS Care in press.
14.
Horner-Johnson W, Dobbertin K, Andresen EM, Iezzoni LI. Breast and cervical cancer screening disparities associated with disability severity. Womens Health Issues. 2014;24:e147–53.PubMedCrossRef
15.
Rees PM, Fowler CJ, Maas CP. Sexual function in men and women with neurological disorders. Lancet. 2007;369:512–25.PubMedCrossRef
16.
Lew-Starowicz M, Rola R. Sexual dysfunctions and sexual quality of life in men with multiple sclerosis. J Sex Med. 2014;11:1294–301.PubMedCrossRef
17.
18.
Kisic-Tepavcevic D, Pekmezovic T, Trajkovic G, et al. Sexual dysfunction in multiple sclerosis: a 6-year follow-up study. J Neurol Sci. 2015;358:317–23.PubMedCrossRef
19.
Celik DB, Poyraz EC, Bingol A, Idiman E, Ozakbas S, Kaya D. Sexual dysfunction in multiple sclerosis: gender differences. J Neurol Sci. 2013;324:17–20.PubMedCrossRef
20.
Souza SS, Castro FA, Mendonca HC, et al. Influence of menstrual cycle on NK activity. J Reprod Immunol. 2001;50:151–9.PubMedCrossRef
21.
Lee S, Kim J, Jang B, et al. Fluctuation of peripheral blood T, B, and NK cells during a menstrual cycle of normal healthy women. J Immunol. 2010;185:756–62.PubMedCrossRef
22.
Reckner Olsson A, Skogh T, Wingren G. Comorbidity and lifestyle, reproductive factors, and environmental exposures associated with rheumatoid arthritis. Ann Rheum Dis. 2001;60:934–9.PubMedCrossRef
23.
Cooper GS, Dooley MA, Treadwell EL, St Clair EW, Gilkeson GS. Hormonal and reproductive risk factors for development of systemic lupus erythematosus: results of a population-based, case-control study. Arthritis Rheum. 2002;46:1830–9.PubMedCrossRef
24.
Whitacre CC, Reingold SC, O’Looney PA. A gender gap in autoimmunity. Science. 1999;283:1277–8.PubMedCrossRef
25.
Papenfuss TL, Powell ND, McClain MA, et al. Estriol generates tolerogenic dendritic cells in vivo that protect against autoimmunity. J Immunol. 2011;186:3346–55.PubMedPubMedCentralCrossRef
26.
Ramagopalan SV, Valdar W, Criscuoli M, et al. Age of puberty and the risk of multiple sclerosis: a population based study. Eur J Neurol. 2009;16:342–7.PubMedCrossRef
27.
• Kavak KS, Teter BE, Hagemeier J, Zakalik K, Weinstock-Guttman B. Higher weight in adolescence and young adulthood is associated with an earlier age at multiple sclerosis onset. Mult Scler. 2015;21:858–65. Adiposity at an early age is associated with an earlier age at MS disease onset. PubMedCrossRef
28.
Sloka JS, Pryse-Phillips WE, Stefanelli M. The relation between menarche and the age of first symptoms in a multiple sclerosis cohort. Mult Scler. 2006;12:333–9.PubMedCrossRef
29.
• Bove R, Chua AS, Xia Z, Chibnik L, De Jager PL, Chitnis T. Complex relation of HLA-DRB1*1501, age at menarche, and age at multiple sclerosis onset. Neurol Genet. 2016;2:e88. The HLA-DRB1*1501 risk allele for MS is inversely correlated with age at menarche, highlighting possible additional complexity in the association between hormonal regulation and genetic risk in determining age at MS onset. PubMedPubMedCentralCrossRef
30.
Lulu S, Graves J, Waubant E. Menarche increases relapse risk in pediatric multiple sclerosis. Mult Scler. 2016;22:193–200.PubMedCrossRef
31.
Emaus A, Espetvedt S, Veierod MB, et al. 17-beta-estradiol in relation to age at menarche and adult obesity in premenopausal women. Hum Reprod. 2008;23:919–27.PubMedCrossRef
32.
Clancy KB, Klein LD, Ziomkiewicz A, Nenko I, Jasienska G, Bribiescas RG. Relationships between biomarkers of inflammation, ovarian steroids, and age at menarche in a rural Polish sample. Am J Hum Biol. 2013;25:389–98.PubMedCrossRef
33.
Kaplowitz PB. Link between body fat and the timing of puberty. Pediatrics. 2008;121(Suppl 3):S208–17.PubMedCrossRef
34.
Lulu S, Graves J, Waubant E. Menarche increases relapse risk in pediatric multiple sclerosis. Mult Scler 2015.
35.
Holmqvist P, Hammar M, Landtblom AM, Brynhildsen J. Age at onset of multiple sclerosis is correlated to use of combined oral contraceptives and childbirth before diagnosis. Fertil Steril. 2010;94:2835–7.PubMedCrossRef
36.
Alonso A, Jick SS, Olek MJ, Ascherio A, Jick H, Hernan MA. Recent use of oral contraceptives and the risk of multiple sclerosis. Arch Neurol. 2005;62:1362–5.PubMedCrossRef
37.
Villard-Mackintosh L, Vessey MP. Oral contraceptives and reproductive factors in multiple sclerosis incidence. Contraception. 1993;47:161–8.PubMedCrossRef
38.
Thorogood M, Hannaford PC. The influence of oral contraceptives on the risk of multiple sclerosis. Br J Obstet Gynaecol. 1998;105:1296–9.PubMedCrossRef
39.
Hernan MA, Hohol MJ, Olek MJ, Spiegelman D, Ascherio A. Oral contraceptives and the incidence of multiple sclerosis. Neurology. 2000;55:848–54.PubMedCrossRef
40.
Hellwig K, Chen LH, Stancyzk FZ, Langer-Gould AM. Oral contraceptives and multiple sclerosis/clinically isolated syndrome susceptibility. PloS one. 2016;11:e0149094.PubMedPubMedCentralCrossRef
41.
Sena A, Couderc R, Vasconcelos JC, Ferret-Sena V, Pedrosa R. Oral contraceptive use and clinical outcomes in patients with multiple sclerosis. J Neurol Sci. 2012;317:47–51.PubMedCrossRef
42.
Gava G, Bartolomei I, Costantino A, et al. Long-term influence of combined oral contraceptive use on the clinical course of relapsing-remitting multiple sclerosis. Fertil Steril 2014.
43.
d’Hooghe MB, Haentjens P, Nagels G, D’Hooghe T, De Keyser J. Menarche, oral contraceptives, pregnancy and progression of disability in relapsing onset and progressive onset multiple sclerosis. J Neurol. 2012;259:855–61.PubMedCrossRef
44.
Pozzilli C, De Giglio L, Barletta VT, et al. Oral contraceptives combined with interferon beta in multiple sclerosis. Neurol Neuroimmunol Neuroinflamm. 2015;e120:2.
45.
Voskuhl RR, Wang H, Wu TC, et al. Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: a randomized, placebo-controlled, phase 2 trial. Lancet Neurol. 2016;15:35–46.PubMedCrossRef
46.
Kotzamani D, Panou T, Mastorodemos V, et al. Rising incidence of multiple sclerosis in females associated with urbanization. Neurology. 2012;78:1728–35.PubMedCrossRef
47.
Weinshenker BG, Hader W, Carriere W, Baskerville J, Ebers GC. The influence of pregnancy on disability from multiple sclerosis: a population-based study in Middlesex County, Ontario. Neurology. 1989;39:1438–40.PubMedCrossRef
48.
Koch M, Uyttenboogaart M, Heersema D, Steen C, De Keyser J. Parity and secondary progression in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2009;80:676–8.PubMedCrossRef
49.
Ramagopalan S, Yee I, Byrnes J, Guimond C, Ebers G, Sadovnick D. Term pregnancies and the clinical characteristics of multiple sclerosis: a population based study. J Neurol Neurosurg Psychiatry. 2012;83:793–5.PubMedCrossRef
50.
Runmarker B, Andersen O. Pregnancy is associated with a lower risk of onset and a better prognosis in multiple sclerosis. Brain. 1995;118(Pt 1):253–61.PubMedCrossRef
51.
D’Hooghe M B, Haentjens P, Nagels G, D’Hooghe T, De Keyser J. Menarche, oral contraceptives, pregnancy and progression of disability in relapsing onset and progressive onset multiple sclerosis. J Neurol 2011.
52.
Verdru P, Theys P, D’Hooghe MB, Carton H. Pregnancy and multiple sclerosis: the influence on long term disability. Clin Neurol Neurosurg. 1994;96:38–41.PubMedCrossRef
53.
Keyhanian K, Davoudi V, Etemadifar M, Amin M. Better prognosis of multiple sclerosis in patients who experienced a full-term pregnancy. Eur Neurol. 2012;68:150–5.PubMedCrossRef
54.
D’Hooghe MB, Nagels G, Uitdehaag BM. Long-term effects of childbirth in MS. J Neurol Neurosurg Psychiatry. 2010;81:38–41.PubMedCrossRef
55.
Karp I, Manganas A, Sylvestre MP, Ho A, Roger E, Duquette P. Does pregnancy alter the long-term course of multiple sclerosis? Ann Epidemiol. 2014;24:504–8. e502PubMedCrossRef
56.
Airas L, Saraste M, Rinta S, Elovaara I, Huang YH, Wiendl H. Immunoregulatory factors in multiple sclerosis patients during and after pregnancy: relevance of natural killer cells. Clin Exp Immunol. 2008;151:235–43.PubMedPubMedCentralCrossRef
57.
Airas L, Nikula T, Huang YH, Lahesmaa R, Wiendl H. Postpartum-activation of multiple sclerosis is associated with down-regulation of tolerogenic HLA-G. J Neuroimmunol. 2007;187:205–11.PubMedCrossRef
58.
D’Hooghe MB, D’Hooghe T, De Keyser J. Female gender and reproductive factors affecting risk, relapses and progression in multiple sclerosis. Gynecol Obstet Invest. 2013;75:73–84.PubMedCrossRef
59.
Vukusic S, Hutchinson M, Hours M, et al. Pregnancy and multiple sclerosis (the PRIMS study): clinical predictors of post-partum relapse. Brain. 2004;127:1353–60.PubMedCrossRef
60.
Portaccio E, Ghezzi A, Hakiki B, et al. Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs. J Neurol Neurosurg Psychiatry. 2014;85:845–50.PubMedCrossRef
61.
Hughes SE, Spelman T, Gray OM, et al. Predictors and dynamics of postpartum relapses in women with multiple sclerosis. Mult Scler. 2014;20:739–46.PubMedCrossRef
62.
•• Alroughani R, Alowayesh MS, Ahmed SF, Behbehani R, Al-Hashel J. Relapse occurrence in women with multiple sclerosis during pregnancy in the new treatment era. Neurology 2018. In the modern treatment era, a higher than previously reported risk of relapse during pregnancy is observed. This seems specifically associated with two high-efficacy therapies (fingolimod and natalizumb), both of which require discontinuation before pregnancy, and both of which have been associated with potential 'rebound' of disease activity upon discontinuation.
63.
Gulick EE. Influence of infant feeding method on postpartum relapse of mothers with MS. International Journal of MS Care. 2002;4:4–14.CrossRef
64.
•• Langer-Gould A, Huang SM, Gupta R, et al. Exclusive breastfeeding and the risk of postpartum relapses in women with multiple sclerosis. Arch Neurol. 2009;66:958–63. This study reports that breastfeeding for greater than 15 months has a protective effect against developing MS. PubMedCrossRef
65.
Hellwig K, Haghikia A, Rockhoff M, Gold R. Multiple sclerosis and pregnancy: experience from a nationwide database in Germany. Ther Adv Neurol Disord. 2012;5:247–53.PubMedPubMedCentralCrossRef
66.
Nelson LM, Franklin GM, Jones MC. Risk of multiple sclerosis exacerbation during pregnancy and breast-feeding. Jama. 1988;259:3441–3.PubMedCrossRef
67.
Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T. Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in multiple sclerosis group. N Engl J Med. 1998;339:285–91.PubMedCrossRef
68.
Portaccio E, Ghezzi A, Hakiki B, et al. Breastfeeding is not related to postpartum relapses in multiple sclerosis. Neurology. 2011;77:145–50.PubMedCrossRef
69.
Pakpoor J, Disanto G, Lacey MV, Hellwig K, Giovannoni G, Ramagopalan SV. Breastfeeding and multiple sclerosis relapses: a meta-analysis. J Neurol. 2012;259:2246–8.PubMedCrossRef
70.
71.
Bove R, Healy BC, Secor E, et al. Patients report worse MS symptoms after menopause: findings from an online cohort. Mult Scle Relat Disord. 2015;4:18–24.CrossRef
72.
Bove R, Healy BC, Musallam A, Glanz BI, De Jager PL, Chitnis T. Exploration of changes in disability after menopause in a longitudinal multiple sclerosis cohort. Mult Scler. 2016;22:935–43.PubMedCrossRef
73.
Bove R, Vaughan T, Chitnis T, Wicks P, De Jager PL. Women’s experiences of menopause in an online MS cohort: a case series. Mult Scler Relat Disord. 2016;9:56–9.PubMedPubMedCentralCrossRef
74.
Joffe H, Guthrie KA, LaCroix AZ, et al. Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms: a randomized clinical trial. JAMA Intern Med. 2014;174:1058–66.PubMedPubMedCentralCrossRef
75.
Bove R, White CC, Fitzgerald KC, et al. Hormone therapy use and physical quality of life in postmenopausal women with multiple sclerosis. Neurology. 2016;87:1457–63.PubMedPubMedCentralCrossRef
76.
Bove R, Alwan S, Friedman JM, et al. Management of multiple sclerosis during pregnancy and the reproductive years: a systematic review. Obstet Gynecol. 2014;124:1157–68.PubMedCrossRef
77.
78.
Singh S, Sedgh G, Hussain R. Unintended pregnancy: worldwide levels, trends, and outcomes. Stud Fam Plann. 2010;41:241–50.PubMedCrossRef
79.
Alwan S, Yee IM, Dybalski M, et al. Reproductive decision making after the diagnosis of multiple sclerosis (MS). Mult Scler. 2013;19:351–8.PubMedCrossRef
80.
Langagergaard V, Pedersen L, Gislum M, Norgard B, Sorensen HT. Birth outcome in women treated with azathioprine or mercaptopurine during pregnancy: a Danish nationwide cohort study. Aliment Pharmacol Ther. 2007;25:73–81.PubMedCrossRef
81.
82.
Ebers GC, Yee IM, Sadovnick AD, Duquette P. Conjugal multiple sclerosis: population-based prevalence and recurrence risks in offspring. Canadian Collaborative Study Group. Ann Neurol. 2000;48:927–31.PubMedCrossRef
83.
Beecham AH, Patsopoulos NA, Xifara DK, et al. Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis. Nat Genet. 2013;45:1353.PubMedPubMedCentralCrossRef
84.
85.
Brown HL, Graves CR. Smoking and marijuana use in pregnancy. Clin Obstet Gynecol. 2013;56:107–13.PubMedCrossRef
86.
ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists. Number 81, May 2007. Obstet Gynecol. 2007;109:1233–48.CrossRef
87.
Aghajafari F, Nagulesapillai T, Ronksley PE, Tough SC, O’Beirne M, Rabi DM. Association between maternal serum 25-hydroxyvitamin D level and pregnancy and neonatal outcomes: systematic review and meta-analysis of observational studies. BMJ. 2013;346:f1169.PubMedCrossRef
88.
Christesen HT, Falkenberg T, Lamont RF, Jorgensen JS. The impact of vitamin D on pregnancy: a systematic review. Acta Obstet Gynecol Scand. 2012;91:1357–67.PubMedCrossRef
89.
Tremlett H, van der Mei IA, Pittas F, et al. Monthly ambient sunlight, infections and relapse rates in multiple sclerosis. Neuroepidemiology. 2008;31:271–9.PubMedCrossRef
90.
Mowry EM, Krupp LB, Milazzo M, et al. Vitamin D status is associated with relapse rate in pediatric-onset multiple sclerosis. Ann Neurol. 2010;67:618–24.PubMed
91.
Mowry EM, Waubant E, McCulloch CE, et al. Vitamin D status predicts new brain magnetic resonance imaging activity in multiple sclerosis. Ann Neurol. 2012;72:234–40.PubMedPubMedCentralCrossRef
92.
Mowry EM. Vitamin D: evidence for its role as a prognostic factor in multiple sclerosis. J Neurol Sci. 2011;311:19–22.PubMedCrossRef
93.
Dobson R, Giovannoni G, Ramagopalan S. The month of birth effect in multiple sclerosis: systematic review, meta-analysis and effect of latitude. J Neurol Neurosurg Psychiatry. 2013;84:427–32.PubMedCrossRef
94.
Chaudhuri A. Why we should offer routine vitamin D supplementation in pregnancy and childhood to prevent multiple sclerosis. Med Hypotheses. 2005;64:608–18.PubMedCrossRef
95.
Grytten N, Torkildsen O, Aarseth JH, et al. Month of birth as a latitude-dependent risk factor for multiple sclerosis in Norway. Mult Scler. 2013;19:1028–34.PubMedCrossRef
96.
Staples J, Ponsonby AL, Lim L. Low maternal exposure to ultraviolet radiation in pregnancy, month of birth, and risk of multiple sclerosis in offspring: longitudinal analysis. Bmj. 2010;340:c1640.PubMedPubMedCentral
97.
Munger KL, Åivo J, Hongell K, Soilu-Hänninen M, Surcel H-M, Ascherio A, et al. status during pregnancy and risk of multiple sclerosis in offspring of women in the Finnish maternity cohort. JAMA Neurol. 2016;73:515–9.PubMedPubMedCentralCrossRef
98.
Demirkiran M, Sarica Y, Uguz S, Yerdelen D, Aslan K. Multiple sclerosis patients with and without sexual dysfunction: are there any differences? Mult Scler. 2006;12:209–14.PubMedCrossRef
99.
Grinsted L, Heltberg A, Hagen C, Djursing H. Serum sex hormone and gonadotropin concentrations in premenopausal women with multiple sclerosis. J Intern Med. 1989;226:241–4.PubMedCrossRef
100.
Lombardi G, Celso M, Bartelli M, Cilotti A, Del Popolo G. Female sexual dysfunction and hormonal status in multiple sclerosis patients. J Sex Med. 2011;8:1138–46.PubMedCrossRef
101.
Sloka JS, Phillips PW, Stefanelli M, Joyce C. Co-occurrence of autoimmune thyroid disease in a multiple sclerosis cohort. J Autoimmune Dis. 2005;2:9.PubMedPubMedCentralCrossRef
102.
Marrie RA, Yu BN, Leung S, et al. The incidence and prevalence of thyroid disease do not differ in the multiple sclerosis and general populations: a validation study using administrative data. Neuroepidemiology. 2012;39:135–42.PubMedCrossRef
103.
Idec B. Tysabri ® (natalizumab) [online]. Accessed June 1.
104.
Idec B. Avonex ® (interferon β-1a) [online]. Available at: www.accessdata.fda.gov/drugsatfda_docs/label/2007/103628s5115lbl.pdf. Accessed 1 June .
105.
Corp. NP. Gilenya ® (fingolimod) [online]. Available at: http://​www.​accessdata.​fda.​gov/​drugsatfda_​docs/​label/​2012/​022527s008lbl.​pdf.​ Accessed 1 June.
106.
Pharmaceuticals T Copaxone ® (glatiramer acetate) [online]. Available at: http://​www.​accessdata.​fda.​gov/​drugsatfda_​docs/​label/​2009/​020622s057lbl.​pdf.​ Accessed June 1.
107.
Alroughani R. Fingolimod-associated amenorrhea: a report of three cases. Mult Scler 2014.
108.
Harward LE, Mitchell K, Pieper C, Copland S, Criscione-Schreiber LG, Clowse ME. The impact of cyclophosphamide on menstruation and pregnancy in women with rheumatologic disease. Lupus. 2013;22:81–6.PubMedCrossRef
109.
Cocco E, Sardu C, Gallo P, et al. Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study. Mult Scler. 2008;14:1225–33.PubMedCrossRef
110.
Linssen WH, Notermans NC, Hommes OR, Rolland R. Amenorrhea after immunosuppressive treatment of multiple sclerosis. Acta Neurol Scand. 1987;76:204–9.PubMedCrossRef
111.
Roux T, Courtillot C, Debs R, Touraine P, Lubetzki C, Papeix C. Fecundity in women with multiple sclerosis: an observational mono-centric study. J Neurol. 2015;262:957–60.PubMedCrossRef
112.
Hellwig K, Correale J. Artificial reproductive techniques in multiple sclerosis. Clin Immunol 2013.
113.
Laplaud DA, Lefrere F, Leray E, Barriere P, Wiertlewski S. Increased risk of relapse in multiple sclerosis patients after ovarian stimulation for in vitro fertilization. Gynecol Obstet Fertil. 2007;35:1047–50.PubMedCrossRef
114.
Hellwig K, Beste C, Brune N, et al. Increased MS relapse rate during assisted reproduction technique. J Neurol. 2008;255:592–3.PubMedCrossRef
115.
Hellwig K, Schimrigk S, Beste C, Muller T, Gold R. Increase in relapse rate during assisted reproduction technique in patients with multiple sclerosis. Eur Neurol. 2009;61:65–8.PubMedCrossRef
116.
Michel L, Foucher Y, Vukusic S, et al. Increased risk of multiple sclerosis relapse after in vitro fertilization. J Neurol Neurosurg Psychiatry. 2012;83:796–802.PubMedCrossRef
117.
Correale J, Farez MF, Ysrraelit MC. Increase in multiple sclerosis activity after assisted reproduction technology. Ann Neurol. 2012;72:682–94.PubMedCrossRef
118.
Coyle PK, Christie S, Fodor P, et al. Multiple sclerosis gender issues: clinical practices of women neurologists. Mult Scler. 2004;10:582–8.PubMedCrossRef
119.
Lu E, Wang BW, Guimond C, Synnes A, Sadovnick D, Tremlett H. Disease-modifying drugs for multiple sclerosis in pregnancy: a systematic review. Neurology. 2012;79:1130–5.PubMedPubMedCentralCrossRef
120.
Bodiguel E, Bensa C, Brassat D, et al. Multiple sclerosis and pregnancy. Rev. Neurol (Paris). 2014;170:247–65.CrossRef
121.
Wundes A, Pebdani RN, Amtmann D. What do healthcare providers advise women with multiple sclerosis regarding pregnancy? Mult Scler Int. 2014;2014:819216.PubMedPubMedCentral
122.
Aventis S. Aubagio ® (teriflunomide) [online]. Available at: http://​www.​accessdata.​fda.​gov/​drugsatfda_​docs/​label/​2012/​202992s000lbl.​pdf.​ Accessed June 1.
123.
Meinl I, Havla J, Hohlfeld R, Kumpfel T. Recurrence of disease activity during pregnancy after cessation of fingolimod in multiple sclerosis. Mult Scler 2017:1352458517731913.
124.
Das G, Damotte V, Gelfand JM, et al. Rituximab before and during pregnancy: a systematic review, and a case series in MS and NMOSD. Neurol Neuroimmunol Neuroinflamm. 2018;5:e453.PubMedPubMedCentralCrossRef
125.
Hellwig K, Gold R. Glatiramer acetate and interferon-beta throughout gestation and postpartum in women with multiple sclerosis. J Neurol. 2011;258:502–3.PubMedCrossRef
126.
Hale TW, Siddiqui AA, Baker TE. Transfer of interferon beta-1a into human breastmilk. Breastfeed Med. 2012;7:123–5.PubMedCrossRef
127.
WHO. Pregnancy, childbirth, postpartum and newborn care—a guide for essential practice, 2006 ed.: World Health Organization, Department of Making Pregnancy Safer, 2006.
128.
de Seze J, Chapelotte M, Delalande S, Ferriby D, Stojkovic T, Vermersch P. Intravenous corticosteroids in the postpartum period for reduction of acute exacerbations in multiple sclerosis. Mult Scler. 2004;10:596–7.PubMedCrossRef
129.
Achiron A, Kishner I, Dolev M, et al. Effect of intravenous immunoglobulin treatment on pregnancy and postpartum-related relapses in multiple sclerosis. J Neurol. 2004;251:1133–7.PubMedCrossRef
130.
Haas J. High dose IVIG in the post partum period for prevention of exacerbations in MS. Mult Scler. 2000;6(Suppl 2):S18–20. discussion S33PubMed
131.
Haas J, Hommes ORA. dose comparison study of IVIG in postpartum relapsing-remitting multiple sclerosis. Mult Scler. 2007;13:900–8.PubMedCrossRef
132.
Orvieto R, Achiron R, Rotstein Z, Noy S, Bar-Hava I, Achiron A. Pregnancy and multiple sclerosis: a 2-year experience. Eur J Obstet Gynecol Reprod Biol. 1999;82:191–4.PubMedCrossRef
133.
Hellwig K, Beste C, Schimrigk S, Immunomodulation CA. postpartum relapses in patients with multiple sclerosis. Ther Adv Neurol Disord. 2009;2:7–11.PubMedPubMedCentralCrossRef
134.
Ost L, Wettrell G, Bjorkhem I, Rane A. Prednisolone excretion in human milk. J Pediatr. 1985;106:1008–11.PubMedCrossRef
135.
Hoes JN, Jacobs JW, Boers M, et al. EULAR evidence-based recommendations on the management of systemic glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2007;66:1560–7.PubMedPubMedCentralCrossRef
136.
Ferrero S, Esposito F, Pretta S, Ragni N. Fetal risks related to the treatment of multiple sclerosis during pregnancy and breastfeeding. Expert Rev Neurotherapeutics. 2006;6:1823–31.CrossRef
137.
ACR. Administraion of contrast media to breast-feeding mothers. In: Media ACoRCoDaC, ed. ACR manual on contrast media, First. ed2013: 97–98.
138.
Webb JA, Thomsen HS, Morcos SK. The use of iodinated and gadolinium contrast media during pregnancy and lactation. Eur Radiol. 2005;15:1234–40.PubMedCrossRef
139.
ACOG. ACOG Committee Opinion. Number 299, September 2004 (replaces No. 158, September 1995). Guidelines for diagnostic imaging during pregnancy. Obstet Gynecol. 2004;104:647–51.CrossRef
140.
AAP. Transfer of drugs and other chemicals into human milk. Pediatrics. 2001;108:776–89.CrossRef
141.
Elliott AB, Chakravarty EF. Immunosuppressive medications during pregnancy and lactation in women with autoimmune diseases. Womens Health (Lond Engl). 2010;6:431–40. quiz 441–432.CrossRef
142.
ACR. ACR Guidelines and Technical Standards. Practice guideline for imaging pregnant or potentially pregnant adolescents and women with ionizing radiation., First. ed. Reston, VA: American College of Radiology, 2008.
143.
Kanal E, Shellock FG, Talagala L. Safety considerations in MR imaging. Radiology. 1990;176:593–606.PubMedCrossRef
144.
Dalmas AF, Texier C, Ducloy-Bouthors AS, Krivosic-Horber R. Obstetrical analgesia and anesthesia in multiple sclerosis. Ann Fr Anesth Reanim. 2003;22:861–4.PubMedCrossRef
145.
Martucci G, Di Lorenzo A, Polito F, Acampa L. A 12-month follow-up for neurological complication after subarachnoid anesthesia in a parturient affected by multiple sclerosis. Eur Rev. Med Pharmacol Sci. 2011;15:458–60.PubMed
146.
Drake E, Drake M, Bird J, Russell R. Obstetric regional blocks for women with multiple sclerosis: a survey of UK experience. Int J Obstet Anesth. 2006;15:115–23.PubMedCrossRef
147.
Vukusic S, Confavreux C. [Multiple sclerosis and pregnancy]. Rev. Neurol (Paris). 2006;162:299–309.CrossRef
148.
Pasto L, Portaccio E, Ghezzi A, et al. Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study. BMC Neurol. 2012;12:165.PubMedPubMedCentralCrossRef
149.
Lu E, Zhu F, van der Kop M, et al. Labor induction and augmentation in women with multiple sclerosis. Mult Scler. 2013;19:1182–9.PubMedCrossRef
150.
151.
Jalkanen A, Alanen A, Airas L. Pregnancy outcome in women with multiple sclerosis: results from a prospective nationwide study in Finland. Mult Scler. 2010;16:950–5.PubMedCrossRef
152.
Dahl J, Myhr KM, Daltveit AK, Hoff JM, Gilhus NE. Pregnancy, delivery, and birth outcome in women with multiple sclerosis. Neurology. 2005;65:1961–3.PubMedCrossRef
153.
Kelly VM, Nelson LM, Chakravarty EF. Obstetric outcomes in women with multiple sclerosis and epilepsy. Neurology. 2009;73:1831–6.PubMedCrossRef
154.
Dahl J, Myhr KM, Daltveit AK, Gilhus NE. Planned vaginal births in women with multiple sclerosis: delivery and birth outcome. Acta Neurol Scand Suppl. 2006;183:51–4.PubMedCrossRef
155.
Chen YH, Lin HL, Lin HC. Does multiple sclerosis increase risk of adverse pregnancy outcomes? A population-based study. Mult Scler. 2009;15:606–12.PubMedCrossRef
156.
Mueller BA, Zhang J, Critchlow CW. Birth outcomes and need for hospitalization after delivery among women with multiple sclerosis. Am J Obstet Gynecol. 2002;186:446–52.PubMedCrossRef
157.
158.
Worthington J, Jones R, Crawford M, Forti A. Pregnancy and multiple sclerosis—a 3-year prospective study. J Neurol. 1994;241:228–33.PubMedCrossRef
159.
Sadovnick AD, Eisen K, Hashimoto SA, et al. Pregnancy and multiple sclerosis. A prospective study. Arch Neurol. 1994;51:1120–4.PubMedCrossRef
160.
161.
Roullet E, Verdier-Taillefer MH, Amarenco P, Gharbi G, Alperovitch A, Marteau R. Pregnancy and multiple sclerosis: a longitudinal study of 125 remittent patients. J Neurol Neurosurg Psychiatry. 1993;56:1062–5.PubMedPubMedCentralCrossRef
162.
Finkelsztejn A, Fragoso YD, Ferreira ML, et al. The Brazilian database on pregnancy in multiple sclerosis. Clin Neurol Neurosurg. 2011;113:277–80.PubMedCrossRef
163.
Ross LE, Grigoriadis S, Mamisashvili L, et al. Selected pregnancy and delivery outcomes after exposure to antidepressant medication: a systematic review and meta-analysis. JAMA Psychiatry. 2013;70:436–43.PubMedCrossRef
164.
O’Hara MW, McCabe JE. Postpartum depression: current status and future directions. Annu Rev. Clin Psychol. 2013;9:379–407.PubMedCrossRef
165.
166.
Arnett PA, Barwick FH, Beeney JE. Depression in multiple sclerosis: review and theoretical proposal. Journal of the International Neuropsychological Society. JINS. 2008;14:691–724.PubMed
167.
Gulick EE, Kim S. Postpartum emotional distress in mothers with multiple sclerosis. J Obstet Gynecol Neonatal Nurs. 2004;33:729–38.PubMedCrossRef
168.
Gulick EE. Adaptation of the postpartum support questionnaire for mothers with multiple sclerosis. Res Nurs Health. 2003;26:30–9.PubMedCrossRef
169.
Gulick EE. Postpartum functioning in mothers with multiple sclerosis. West J Nurs Res. 2007;29:589–602. discussion 603–512PubMedCrossRef
Metadaten
Titel
Caring for Women with Multiple Sclerosis Across the Lifespan
verfasst von
Kelsey Rankin
Riley Bove
Publikationsdatum
01.07.2018
Verlag
Springer US
Erschienen in
Current Neurology and Neuroscience Reports / Ausgabe 7/2018
Print ISSN: 1528-4042
Elektronische ISSN: 1534-6293
DOI
https://doi.org/10.1007/s11910-018-0846-2

Weitere Artikel der Ausgabe 7/2018

Current Neurology and Neuroscience Reports 7/2018 Zur Ausgabe

Sleep (M Thorpy and M Billiard, Section Editors)

Narcolepsy Associated with Pandemrix Vaccine

Headache (R Halker, Section Editor)

Women and Migraine: the Role of Hormones

Behavior (H S Kirshner, Section Editor)

Thalamic Lesions and Aphasia or Neglect

Sleep (M Thorpy and M Billiard, Section Editors)

Sleep in Children with Congenital Malformations of the Central Nervous System

Demyelinating Disorders (J Bernard and M Cameron, Section Editors)

Behçet’s Syndrome and Nervous System Involvement

Sleep (M Thorpy and M Billiard, Section Editors)

The Sleep Disorder in Anti-lgLON5 Disease

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Kostenlos registrieren

Neu im Fachgebiet Neurologie

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Frühe Alzheimertherapie lohnt sich

25.04.2024 AAN-Jahrestagung 2024 Nachrichten

Ist die Tau-Last noch gering, scheint der Vorteil von Lecanemab besonders groß zu sein. Und beginnen Erkrankte verzögert mit der Behandlung, erreichen sie nicht mehr die kognitive Leistung wie bei einem früheren Start. Darauf deuten neue Analysen der Phase-3-Studie Clarity AD.

Viel Bewegung in der Parkinsonforschung

25.04.2024 Parkinson-Krankheit Nachrichten

Neue arznei- und zellbasierte Ansätze, Frühdiagnose mit Bewegungssensoren, Rückenmarkstimulation gegen Gehblockaden – in der Parkinsonforschung tut sich einiges. Auf dem Deutschen Parkinsonkongress ging es auch viel um technische Innovationen.

Demenzkranke durch Antipsychotika vielfach gefährdet

23.04.2024 Demenz Nachrichten

Wenn Demenzkranke aufgrund von Symptomen wie Agitation oder Aggressivität mit Antipsychotika behandelt werden, sind damit offenbar noch mehr Risiken verbunden als bislang angenommen.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen
Bildnachweise